Yale University  

Calendar

A-Z Index

Translational Nanomedicine Panel


Mark Saltzman, PhD - Moderator

Goizueta Foundation Professor of Biomedical Engineering, Chemical & Environmental Engineering & Physiology
Yale

Alexandra Glucksmann, PhD

Senior Vice President, Research and Development
Cerulean

Sandra has provided leadership in a variety of functions since Cerulean’s founding and has served as our head of R&D since 2011. Prior to joining Cerulean, she spent 13 years at Millennium Pharmaceuticals, which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately becoming vice president of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the chief executive officer and led company-wide process improvement initiatives and participated in business development and merger and acquisition efforts. During her tenure at Millennium, Sandra was critical in transitioning Millennium from a genomics research-focused organization to a fully integrated pharmaceuticals company with products on the market. Her division played an integral role in the numerous Millennium-large pharmaceutical company collaborations, which generated over $1.8 billion in funding for the company.

Sandra serves on the board of directors of Taconic Farms and is the chair of the board of Women Entrepreneurs in Science and Technology. She is also a member of the Genetics Advisory Council of the Harvard-Partners Center for Personalized Genetic Medicine. Sandra earned her B.S. from the University of Wisconsin in Madison, her Ph.D., with honors, from the University of Chicago and completed her post-doctoral training at the Massachusetts Institute of Technology.

Quentin Pankhurst, PhD

Director of the Institute of Biomedical Engineering
University College London

The objective of the IBME is to bring together UCL’s excellence in academic and clinical R&D – around a thousand staff, fellows, nurses and students in 35 different centers, departments and institutes – to create a world leading research center for biomedical engineering. The IBME’s goal is to be the world’s fastest and most cost-effective deliverer of patient benefit by harnessing the power of university-based innovation and experimental medicine in the UK.

Quentin is also the Director of the Davy-Faraday Research Laboratory and Wolfson Professor of Natural Philosophy – a post once held by Lord Ernest Rutherford – at the Royal Institution of Great Britain, in London. Here he runs research programs in bio- and nanomagnetism aimed at making practical advances in the use of magnetic nanoparticles in healthcare. These include medical imaging devices, targeted regenerative medicine, molecular imaging microscopy for living cells, and the development of multi-functional nanoparticles for therapy and diagnostics.

Quentin is a founder and CTO of Endomagnetics Ltd, a spin-out company which is commercializing the SentiMag™, an intra-operative device for breast cancer surgery.

Karim Dabbagh, PhD

Executive Director and Head, External R&D and Innovation Research Units
Pfizer Worldwide R&D

Karim collaborates with Pfizer WRD leaders to create and draw on global innovative external opportunities in both the biotech and academic space to strengthen Pfizer’s Inflammation and Immunology pipeline via the strategic integration of select assets and technologies.

Karim spent nine years at Roche Palo Alto where he was last Head of Inflammation Discovery Research prior to becoming the founder of the start-up company Modus BioMedicine (treatment of transplantation and autoimmune disease).

Karim received his Ph.D. in Biochemistry from University College, London and completed postdoctoral fellowships at the Cardiovascular Research Institute at University of California, San Francisco and at Stanford University in the Department of Pediatrics, Division of Immunology.

Translational Cardiology Panel


Michael Simons, MD - Moderator

Robert W. Berliner Professor of Medicine, Professor - Cell Biology, Section Chief - Cardiovascular Medicine; Director - Yale Cardiovascular Research Center

Larry Deckelbaum, PhD

Vice President, Scientific Partnership Strategy, Cardiovascular & Metabolism (CVM) Therapeutic Area
Janssen Pharmaceutical Companies of Johnson & Johnson

Larry was formerly External Innovation Head (CVM) at Janssen, and has held the positions of Franchise Development Leader (Cardiovascular Medicine) at J&J PRD, and head of the General Medicine Clinical Research and Development Department at Centocor. Prior to joining J&J, Larry was director of Clinical Research-Cardiovascular at Merck Research Laboratories; associate professor at Yale University School of Medicine; and director of the Cardiac Catheterization Laboratory at the Veteran's Administration (VA) Medical Center in West Haven, Connecticut. Larry has extensive clinical and preclinical research experience and has authored numerous articles in the fields of interventional and acute care cardiology.

Larry is a graduate of Massachusetts Institute of Technology and Harvard Medical School. He completed his medical residency and cardiology clinical and research fellowship at the Brigham and Women’s Hospital, and West Roxbury VA Medical Center. His post-graduate fellowship training was at Tufts-New England Medical Center.

Sotirios K. Karathanasis, PhD

Executive Director Strategy & Externalization Cardiovascular and Gastrointestinal Diseases
AstraZeneca

Sotirios holds a Doctor of Philosophy in biochemistry from the University of Georgia. He previously served as the Chief Scientific Officer of endocrine and cardiovascular research for Eli Lilly, Director of Cardiovascular Pharmacology for Pfizer and Associate Professor of the Departments of Cardiology and Physiology for Harvard Medical School.

 
Top of page.